We are investigating the efficacy and safety of enhanced thromboprophylaxis during neoadjuvant treatments for pancreatic cancer.
Conditions
Brief summary
As primary endpoints, we collect venous and arterial thrombotic events, bleeding complications, as well as information on disease progression and feasible time and cause of death. Patients are followed for at least five years or until death.
Detailed description
We will observe changes in the patient's coagulation activation from venous blood samples during neoadjuvant treatment and disease follow-up. Blood samples will be taken before the start of neoadjuvant treatments, between chemotherapy cycles, after neoadjuvant treatments, and (or after the start of palliative treatments if surgery is not feasible) at months 1, 3, 6, 12, 15, 24, and 36 along with other scheduled blood tests.
Interventions
DRUGinnohep® 3500 anti-Xa IU injektioneste
DRUGliuos
DRUGkerta-annosruiskussa
DRUGInhixa 6
DRUG000 IU (60 mg)/0.6 mL solution for injection in pre-filled syringe
Sponsors
HUS-Yhtymae, University Of Helsinki
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| As primary endpoints, we collect venous and arterial thrombotic events, bleeding complications, as well as information on disease progression and feasible time and cause of death. Patients are followed for at least five years or until death. | — |
Secondary
| Measure | Time frame |
|---|---|
| We will observe changes in the patient's coagulation activation from venous blood samples during neoadjuvant treatment and disease follow-up. Blood samples will be taken before the start of neoadjuvant treatments, between chemotherapy cycles, after neoadjuvant treatments, and (or after the start of palliative treatments if surgery is not feasible) at months 1, 3, 6, 12, 15, 24, and 36 along with other scheduled blood tests. | — |
Countries
Finland
Outcome results
None listed